8-K: InnovAge Reports Strong Growth, Profitability at JPM Conference

InnovAge Holding Corp. presented a robust growth trajectory and expanding profitability at its January 2026 investor conference, highlighting its unique PACE model for complex seniors.

Summary

• InnovAge operates 20 care centers (with 2 under development) across 6 states, serving approximately 7,890 participants as of September 30, 2025.
• The company reported a revenue growth CAGR of 17.4% from 1QFY23 to 1QFY26, with revenues increasing from $171.2 million to $236.1 million.
• Adjusted EBITDA margin for 1QFY26 reached 7.5%, and the company generated $44.3 million in positive operating cash flow on a trailing twelve-month basis as of September 30, 2025.
• InnovAge projects Fiscal Year 2026 total revenue between $900 million and $950 million, with Adjusted EBITDA expected to be between $56 million and $65 million.
• The company's PACE model serves medically and socially complex seniors, demonstrating superior outcomes such as 10% lower inpatient admissions and over 40% lower 30-day readmission rates compared to industry benchmarks.
• InnovAge is expanding through responsible organic growth, operating leverage, selective partnerships, and disciplined expansion, including joint ventures with Orlando Health and Tampa General Hospital.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with strong financial performance, clear growth strategies, and superior patient outcomes. The company is demonstrating consistent progress in profitability and market expansion, despite acknowledging ongoing litigation and de novo investment costs.

Positives

• Achieved a 17.4% revenue growth CAGR from 1QFY23 to 1QFY26, reflecting strong top-line expansion.
• Reported a 7.5% Adjusted EBITDA margin for 1QFY26, indicating improving operational efficiency and profitability.
• Generated $44.3 million in positive operating cash flow on a trailing twelve-month basis as of September 30, 2025, demonstrating financial health.
• Projected Fiscal Year 2026 Adjusted EBITDA of $56 million to $65 million, signaling continued profitability growth.
• InnovAge's care model shows superior outcomes, including 10% lower inpatient admissions per 1,000 (634 vs. 704 for FFS Frail Elderly) and over 40% lower RAF Adjusted 30-day readmission rates (~8% vs. ~15% for Medicare Advantage).
• Maintains significantly lower voluntary disenrollment rates (~7% vs. ~16% for Medicare Advantage), indicating high participant satisfaction and retention.
• The company's PMPM medical costs have a modest CAGR of 1.8% from FY23 to FY25 ($7,584 to $7,854), suggesting effective cost management.
• The PACE market is large and underpenetrated, with strong bipartisan policy support for expansion, reducing long-term regulatory risk.

Negatives

• The company anticipates $13.4 million to $15.4 million in de novo losses for Fiscal Year 2026, indicating upfront investment costs for new centers.
• The non-GAAP reconciliation footnotes detail ongoing litigation costs and settlements, including a $10.1 million accrual for a potential stockholder class action settlement.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to vary materially.
• Ongoing macroeconomic challenges, including an increased competitive labor market and inflation, could impact operations and financial performance.
• The company faces risks related to legal proceedings, including litigation by stockholders, civil investigative demands, and arbitration with a former pharmacy provider.
• Challenges in increasing the number of participants, growing enrollment and capacity within existing and new centers, and building additional de novo centers.
• Risks associated with expanding into new geographies and executing tuck-in acquisitions or joint ventures.
• Uncertainties regarding reimbursement and regulatory developments could affect the business model.
• Achievement of mid-term and long-term financial goals, including margin targets, is subject to the rate of de novo openings and magnitude of operating losses, among other factors.

Future Outlook

InnovAge anticipates continued growth and margin expansion over the next two years by optimizing its platform through a technology-first, integrated ecosystem, advancing clinical analytics, and scaling with fixed-cost discipline. The company aims for an 8-9% Adjusted EBITDA margin in the next 1-2 years, with a sustainable run margin at 10%+. Fiscal Year 2026 guidance projects total revenue between $900 million and $950 million and Adjusted EBITDA between $56 million and $65 million, with participant census expected to reach 7,900-8,100.

Management Comments

• "InnovAge is a scaled, vertically integrated payor-provider platform delivering personalized, value-based care to high-acuity, dual-eligible seniors."
• "Our proven model of care is preferred by participants and their families."
• "Operational discipline is translating into growth and profitability."
• "The PACE model is designed to care for medically and socially complex, nursing-home-eligible seniors where other value-based models struggle to operate economically."
• "Multi-year investments in technology, operations, and clinical integration are translating into consistent growth, margin expansion, and positive cash flow."
• "InnovAge is positioned to drive value through responsible organic growth, operating leverage, selective partnerships, and disciplined expansion from a single scalable platform."
• "Our partnership with InnovAge reflects our continued work to break down barriers and bring comprehensive, coordinated health care directly to those who need it most." John Couris, President & CEO, TGH (referencing a joint venture).

Industry Context

InnovAge operates within the Program of All-Inclusive Care for the Elderly (PACE) sector, which serves a small fraction of eligible seniors despite strong bipartisan policy support for expansion. The company is highly differentiated by its scale and diversification compared to the largely subscale, single-state players in the PACE market. InnovAge's full-risk payor-provider model, which integrates care delivery with financial accountability, positions it uniquely against traditional provider-led or payor-led models that often involve fragmented accountability and delegated risk. The market is experiencing tailwinds from the accelerating growth of the dual-eligible demographic and the emergence of for-profit entrants with capital to drive growth.

Comparison to Industry Standards

• InnovAge's target panel size of less than 100 participants per Primary Care Provider (PCP) is significantly lower than the 500+ for traditional value-based care providers, allowing for more personalized care.
• InnovAge PCPs average 5 participant clinic visits per day, compared to 20-25 in other models, indicating a higher-touch approach.
• The company's inpatient admission rate of 634 per 1,000 participants is 10% lower than the 704 per 1,000 for FFS Frail Elderly beneficiaries.
• InnovAge's risk-adjusted 30-day readmission rate of approximately 8% is over 40% lower than the approximately 15% seen in Medicare Advantage plans.
• Voluntary disenrollment from InnovAge programs is less than 50% of that in Medicare Advantage, at approximately 7% compared to approximately 16%.
• InnovAge achieves 12% lower costs compared to a comparable population under Medicaid, demonstrating cost-effectiveness.
• The average Risk Adjustment Factor (RAF) for InnovAge participants is 2.42, significantly higher than the Medicare average of 1.03, indicating they serve a much more medically complex population.

Legal Proceedings

• Ongoing litigation by stockholders, civil investigative demands, and arbitration with a former pharmacy provider.
• Accrued $10.1 million in connection with the potential settlement of a previously disclosed stockholder class action (as of June 30, 2025, and September 30, 2025).

Stakeholder Impact

• **Shareholders:** Positive impact due to accelerating growth, expanding margins, and projected profitability, indicating potential for increased shareholder value.
• **Participants/Patients:** Highly positive impact through a comprehensive, personalized, and high-touch care model designed to enable frail seniors to live independently and avoid nursing homes, leading to superior health outcomes.
• **Employees:** Potential for growth and stability within a scaled, multi-state platform, though the filing mentions costs related to organizational restructure.
• **Government Payors (Medicare/Medicaid):** Positive impact through meaningful savings delivered by InnovAge's end-to-end accountability for the healthcare dollar and lower costs compared to comparable populations.
• **Partners (e.g., Orlando Health, TGH):** Strengthened clinical networks and integrated care delivery ecosystems, enhancing referrals and supporting aging in place.

Next Steps

• Optimize the platform over the next two years through a technology-first, integrated ecosystem.
• Advance clinical analytics to proactively manage risk and improve outcomes.
• Scale operations with fixed-cost discipline to unlock operating leverage.
• Expand selectively into complementary markets, products, and opportunities.
• Continue to drive responsible organic growth and execute on selective partnerships and disciplined expansion.

Key Dates

Recommendation

The filing provides a comprehensive update on InnovAge's strong operational improvements, consistent growth, and expanding profitability, supported by positive financial guidance for FY26. The company's unique PACE model demonstrates superior outcomes and cost-effectiveness in a growing market. While the outlook is positive, this is a routine investor presentation rather than a new earnings report or unexpected material event. The information reinforces the company's strategic direction and execution, suggesting a 'hold' for investors who are already positioned, as the positive trends are largely in line with the company's stated strategy and previous communications. New investors might consider initiating a position based on the strong fundamentals and market tailwinds, but without new, unexpected catalysts, a 'hold' is appropriate for existing positions.

Keywords

PACE, Program of All-Inclusive Care for the Elderly, Value-Based Care, Senior Healthcare, Dual-Eligible, Medicare, Medicaid, Integrated Care, Healthcare Provider, Financial Performance, Growth Strategy